How many drugs treat Sinus headache?

Drug Landscape tracks 10 marketed treatments for Sinus headache (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/sinus-headache.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sinus headache — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sinus headache (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Sinus headache, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Sudafed	pseudoephedrine	Generic (multiple manufacturers)	Nasal decongestant (sympathomimetic)	Alpha-1A adrenergic receptor, Alpha-2A adrenergic receptor, Beta-2 adrenergic receptor	1976-01-01
Aleve	naproxen	Generic (originally Syntex)	NSAID	Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1	1976-01-01
Sudafed PE	phenylephrine	Generic (multiple manufacturers)	Alpha-1 adrenergic agonist (decongestant/vasopressor)	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor	1976-01-01
Pyrilamine	mepyramine	Impax Labs	Central Nervous System Stimulant [EPC]	Histamine H1 receptor	1973-01-01
Advil	ibuprofen	Generic (originally Boots Group)	Nonsteroidal Anti-inflammatory Drug [EPC]	Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2	1969-01-15
Acetaminophen	Paracetamol	Polymedica	acetaminophen	Transient receptor potential cation channel subfamily V member 4	1968-01-01
Mucinex	guaifenesin	Generic (multiple manufacturers)	Expectorant [EPC]	Vagal gastric reflex → increased respiratory secretions	1952-01-01
Phenergan Vc W/ Codeine	PHENYLEPHRINE BITARTRATE	ANI Pharmaceuticals	Nonsteroidal Anti-inflammatory Drug [EPC]	Alpha-1B adrenergic receptor	1952-01-01
Norgesic	acetylsalicylic acid	Endo	centrally acting muscle relaxant with anticholinergic properties	reticular formation (brain stem)	1950-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Generic (multiple manufacturers) · 3 drugs in Sinus headache
· 2 drugs in Sinus headache
Alpharma Us Pharms · 1 drug in Sinus headache
Endo · 1 drug in Sinus headache
Generic (originally Boots Group) · 1 drug in Sinus headache
Generic (originally Syntex) · 1 drug in Sinus headache
Hikma · 1 drug in Sinus headache
Impax Labs · 1 drug in Sinus headache
Polymedica · 1 drug in Sinus headache
ANI Pharmaceuticals · 1 drug in Sinus headache

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Sinus headache:

Cite this brief

Drug Landscape (2026). Sinus headache — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sinus-headache. Accessed 2026-06-10.

Sinus headache full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing